Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 13, 2023 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Webcast Conference Call of First Quarter 2023 Financial Results on May 4, 2023

CAMBRIDGE, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
April 03, 2023 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Publishes 2023 Environmental, Social and Governance (ESG) Report

– Report Highlights Continued Progress on Patient Access, Health Equity, Diversity and Flexibility – – Aligns with the Sustainability Accounting Standards Board (SASB) Standards for the...
March 02, 2023 08:26 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Participate in March Investor Conferences

CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
February 28, 2023 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Launches “Red Cell Revolution” in Recognition of Rare Disease Day

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
February 23, 2023 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Reports Fourth Quarter and Full Year 2022 Financial Results

– Completed Enrollment in Phase 2 RISE UP Study of PYRUKYND® (mitapivat) in Sickle Cell Disease – – On Track to Complete Enrollment in Phase 3 ENERGIZE and ENERGIZE-T Studies of PYRUKYND® in...
February 02, 2023 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Webcast Conference Call of Fourth Quarter and Year End 2022 Financial Results on Feb. 23, 2023

CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
January 08, 2023 20:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company’s Vision to Transform Patient Outcomes in Rare Diseases

– Consistent and compelling clinical data across rare hematological diseases support five ongoing pivotal trials in thalassemia, sickle cell disease and pediatric pyruvate kinase (PK) deficiency – –...
January 03, 2023 17:57 ET | Source: Agios Pharmaceuticals, Inc.

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
December 21, 2022 08:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023

CAMBRIDGE, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
December 11, 2022 19:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

– Data Suggest Long-term Treatment with PYRUKYND® in Adults with PK Deficiency is Associated with Improvements in Hemoglobin, Iron Overload, Transfusion Burden and Patient-reported Outcomes,...